Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen
NCT04026269
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
MOAP
Sponsor
Han weidong